Is there a best TKI for chronic phase CML?

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) management has been revolutionized by BCR/ABL1 tyrosine kinase inhibitors (TKIs).
• Five oral, effective, and generally well-tolerated TKIs are now available for CML treatment.
• Indefinite TKI therapy necessitates careful consideration of long-term safety and patient quality of life.

Purpose of the Study:

• To guide optimal selection and utilization of BCR/ABL1 TKIs for individual Ph+ CML patients.
• To ensure the best duration and quality of life while avoiding treatment complications and minimizing costs.
• To highlight the importance of understanding distinct benefits, risks, and patient-specific factors in TKI selection.

Main Methods:

• Review of evidence-based care guidelines for Ph+ CML.
• Analysis of efficacy, early and late toxicities of available TKIs.
• Consideration of patient-specific factors including risk status, age, and comorbidities.

Main Results:

• TKI therapy has significantly improved outcomes across all stages of Ph+ CML.
• Optimal TKI selection requires balancing efficacy with long-term safety profiles.
• Molecular monitoring and achieving treatment milestones are critical for prognostic assessment.

Conclusions:

• Treatment choice among TKIs is multifactorial, extending beyond mere efficacy.
• Individualized TKI selection is paramount for maximizing patient benefit and minimizing adverse events.
• Understanding the unique risk-benefit profiles of each TKI is essential for effective Ph+ CML management.